Synthesis and central none-opioid analgesic activity of SIPI5047.
- Author:
Jian-Qi LI
1
;
Li-Ying HUANG
;
Xin-Jian CHEN
;
Zhi-Jie WENG
;
Chun-Nian ZHANG
Author Information
1. Shanghai Institute of Pharmaceutical Industry, Shanghai 200040, China. lijq@sipi.com.cn
- Publication Type:Journal Article
- MeSH:
Analgesics;
chemical synthesis;
pharmacology;
toxicity;
Animals;
Female;
Male;
Mice;
Motor Activity;
drug effects;
Pain Measurement;
methods;
Piperazines;
chemical synthesis;
pharmacology;
toxicity;
Random Allocation;
Rats;
Rats, Sprague-Dawley;
Receptors, N-Methyl-D-Aspartate;
antagonists & inhibitors;
Receptors, Opioid, mu;
metabolism;
Substance-Related Disorders;
etiology
- From:
Acta Pharmaceutica Sinica
2008;43(6):611-618
- CountryChina
- Language:Chinese
-
Abstract:
Compound SIPI5047 was synthesize by using piperazine as starting material in five reaction steps, and its central none-opioid analgesic activity was studied. Its analgesic activity, pharmacological mechanism, action type and drug dependence were well studied in vivo and in vitro. The results show that SIPI5047 has potent analgesic activities in vivo, which is quite similar to morphine and also much more powerful than paracetamol. SIPI5047 has no efficacy to reduce fever or inflammation, but has an obvious action on central nervous system. SIPI5057 has no apparent affinity with the mu-receptor and it is an antagonist that acts on the polyamine site of the NMDA receptor. SIPI5057 appears no drug dependence. SIPI5047 is a novel central none-opioid analgesic agent and more worthy of further research as a new drug candidate.
